Investor webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology.

In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers.

The webinar will be held on:

EDT: Tuesday March 11, 5.30pm  
AEDT: Wednesday March 12, 8.30am

The event will run for approximately 1.5 hours.

Rewatch the webinar here

Presentations
Neeraj Agarwal, MD

Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT

ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix’s investigational prostate cancer therapy
Eric Jonasch, MD

Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX

STARLITE studies of TLX250 (177Lu girentuximab) in combination with immunotherapy
Rodney Hicks, MD

Professor of Medicine at the University of Melbourne and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in Australia

TLX592 (64Cu/225Ac RADmAb®) and the role of alpha therapies in the treatment of prostate cancer

Presenters